Impact News +++ INOVIO Pharmaceuticals proposes securities offering (SeekingAlpha) +++ INOVIO Aktie -12,75%

Gewinn & Umsatz News zur INCYTE Aktie

>INCYTE Aktienkurs

80.92 EUR (TradegateBSX)

Ask: 81.32 EUR / 122 Stück

Bid: 80.52 EUR / 123 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INCYTE Aktie über LYNX handeln

Intraday

1 Jahr

>INCYTE Performance

1 Woche: +1,3%

1 Monat: -3,4%

3 Monate: -3,7%

6 Monate: +9,3%

1 Jahr: +44,9%

laufendes Jahr: -3,7%

>INCYTE Aktie

Name:

INCYTE DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45337C1027 / 896133

Symbol/ Ticker:

ICY (Frankfurt) / INCY (NASDAQ)

Kürzel:

FRA:ICY, ETR:ICY, ICY:GR, NASDAQ:INCY

Index:

S&P500

Webseite:

https://incyte.com/

Profil:

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunity. Its portfolio features key products such as JAK..
>Volltext..

Marktkapitalisierung:

15543.42 Mio. EUR

Unternehmenswert:

12568.26 Mio. EUR

Umsatz:

4445.27 Mio. EUR

EBITDA:

1241.64 Mio. EUR

Nettogewinn:

1112.48 Mio. EUR

Gewinn je Aktie:

5.7 EUR

Schulden:

47.49 Mio. EUR

Liquide Mittel:

2678.46 Mio. EUR

Operativer Cashflow:

1222.15 Mio. EUR

Bargeldquote:

2.36

Umsatzwachstum:

6.84%

Gewinnwachstum:

3377.11%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 1.759.178 USD.

Suchwörter:

INCYTE

Letzte Datenerhebung:

02.04.26

>INCYTE Kennzahlen

Aktien/ Unternehmen:

Aktien: 199.01 Mio. St.

Frei handelbar: 98.98%

Leerverk. Aktien: 5.55%

Rückkaufquote: -1.13%

Mitarbeiter: 2844

Umsatz/Mitarb.: 1.56 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 18.56%

Bewertung:

KGV: 14.51

KGV lG: 12.21

KUV: 3.57

KBV: 3.57

PEG-Ratio: 0.01

EV/EBITDA: 10.12

Rentabilität:

Bruttomarge: 91.47%

Gewinnmarge: 25.03%

Operative Marge: 26.12%

Managementeffizenz:

Gesamtkaprendite: 20.66%

Eigenkaprendite: 29.87%

>INCYTE Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>INCYTE Chart & Kurs - NASDAQ

>INCYTE Gewinn & Umsatz News

10.02.26 - 14:06	Incyte Corporation Q4 Profit Increases, Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) announced earnings for its fourth quarter that Increased from last year and beat the Street estimates.The company's bottom line totaled $299.3 mill......

28.10.25 - 13:18	Incyte Corporation Q3 Profit Increases, Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) revealed a profit for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings totaled ......

17.09.25 - 08:48	Incyte Reports Encouraging 24-Week Results From Phase 3 STOP-HS Program Of Povorcitinib (AFX)
	WASHINGTON (dpa-AFX) - Incyte Corporation (INCY) on Wednesday announced encouraging 24-week data from the pivotal Phase 3 STOP-HS program evaluating povorcitinib in adults with hidradenitis suppur......

29.07.25 - 15:01	Incyte Q2 Results Top Estimates (AFX)
	WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) on Tuesday reported net income of $405.0 million or $2.04 per share for the second quarter, compared to a net loss of $444.60 million or $2.04 per share ......

10.07.25 - 15:06	Incyte′s Q2 2025 Earnings: What to Expect (Barchart)
	Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge in profitability, projecting triple-digit year-over-year profit growth....

29.04.25 - 14:18	Incyte Q1 Results Top Estimates (AFX)
	WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) on Tuesday reported net income of $158.20 million or $0.80 per share for the first quarter, lower than $169.55 million or $0.75 per share in the prior-ye......

16.04.25 - 13:30	Incyte Earnings Preview: What to Expect (Barchart)
	Incyte is all set to release its fiscal first-quarter earnings later this month, and analysts project a high double-digit profit growth....

09.03.25 - 04:01	Lilly Reveals Positive Phase 3 Results For Adolescent Alopecia Areata Treatment With Baricitinib (AFX)
	INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) and Incyte's (INCY) late-breaking results from Phase 3 BRAVE-AA-PEDS study found adolescent patients (ages 12 to under 18) with severe alopecia are......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Don′t marry, be happy. - Hera Lind

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram